Abbott vs. Johnson & Johnson in 2026 debate turns on valuation vs. litigation risk
A market comparison weighing Abbott Laboratories’ lower valuation against Johnson & Johnson’s stronger profitability framed the key trade-off as pricing power versus ongoing talc-related legal overhang.